{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:06:14Z","timestamp":1784786774833,"version":"3.55.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Despite the rapid scale-up of early infant diagnosis and antiretroviral therapy, pediatric HIV type 1 (HIV-1) remains a remarkable public health as children account for 15% of all AIDS-related deaths worldwide. Broadly neutralizing antibodies (bNAbs) have emerged as a promising strategy for the prevention, treatment, and potential cure of HIV. In adults, bNAbs have proven to be safe and effective, capable of suppressing plasma viremia and delaying viral rebound during analytical treatment interruptions. bNAbs provide immediate passive immunity and long-acting coverage, which makes them suitable for children where high baseline viral loads drive rapid disease progression and reservoir establishment. Several trials have demonstrated that subcutaneous administration of bNAbs is safe and pharmacokinetically feasible in neonates and have provided a proof-of-concept for bNAb-mediated viral control in children. However, the clinical evaluation of bNAbs has primarily been directed towards adult populations in the Global North, leading to limited pediatric clinical data. This research lag represents a critical ethical inequity that risks denying life-saving therapeutics to the most vulnerable populations. Therefore, equitable access in the Global South requires the elimination of structural barriers that currently delay pediatric access through a strategy of intentional early inclusion, technology transfer, and parallel clinical development. Similarly, a multi-faceted approach involving governments in the Global South, funders, stakeholders, and pharmaceutical developers is essential to address intellectual property sharing, licensing, regulatory harmonization, and local manufacturing. The ongoing development of pediatric trials represents an opportunity to achieve long-term viral remission, providing a definitive pathway to end the pediatric HIV epidemic. Prioritizing these studies is a scientific and moral necessity to ensure that children are finally placed at the center of medical innovations and no longer excluded from therapeutic advancements.<\/jats:p>","DOI":"10.3389\/fped.2026.1833681","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:39:00Z","timestamp":1784785140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Broadly neutralizing antibodies for treatment of HIV in children in the Global South: rationale and challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Alfredo","family":"Tagarro","sequence":"first","affiliation":[{"name":"Innovation in Global Paediatric Infectious Diseases Research Group, Instituto de Investigaci\u00f3n 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Department of Pediatrics, Infanta Sof\u00eda University Hospital. Fundaci\u00f3n Para la Investigaci\u00f3n Biom\u00e9dica e Innovaci\u00f3n Hospital Universitario Infanta Sof\u00eda y Hospital del Henares (FIIB HUIS HHEN)","place":["Madrid, Spain"]},{"name":"Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid","place":["Madrid, Spain"]},{"name":"CIBER in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Cobela-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Innovation in Global Paediatric Infectious Diseases Research Group, Instituto de Investigaci\u00f3n 12 de Octubre (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Malhotra","sequence":"additional","affiliation":[{"name":"IAVI","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chapman","sequence":"additional","affiliation":[{"name":"IAVI","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rojo","sequence":"additional","affiliation":[{"name":"Innovation in Global Paediatric Infectious Diseases Research Group, Instituto de Investigaci\u00f3n 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102648","DOI":"10.1016\/j.eclinm.2024.102648","article-title":"High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries","volume":"23","author":"Tagarro","year":"2024","journal-title":"EClinMed"},{"key":"B3","doi-asserted-by":"publisher","first-page":"105788","DOI":"10.1016\/j.antiviral.2023.105788","article-title":"Next-generation bNAbs for HIV-1 cure strategies","volume":"222","author":"Schriek","year":"2024","journal-title":"Antiviral Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","article-title":"An overview of human anti-HIV-1 neutralizing antibodies against diverse epitopes of HIV-1","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41590-025-02286-5","article-title":"Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bNAb for HIV-1 prevention and therapy","volume":"26","author":"Gieselmann","year":"2025","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.virusres.2017.10.011","article-title":"Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies","volume":"43","author":"Sun","year":"2018","journal-title":"Virus Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e23532","DOI":"10.1371\/journal.pone.0023532","article-title":"Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting","volume":"6","author":"Morris","year":"2011","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"P91","DOI":"10.1186\/1742-4690-9-S2-P91","article-title":"Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture","volume":"9","author":"Longo","year":"2012","journal-title":"Retrovirology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11904-025-00744-1","article-title":"Future of bNAbs in HIV treatment","volume":"22","author":"Tebas","year":"2025","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly neutralizing antibodies for HIV-1 prevention","volume":"20","author":"Walsh","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1004329","DOI":"10.1371\/journal.pmed.1004329","article-title":"Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127\/HPTN 087): a phase I randomized clinical trial","volume":"21","author":"Walsh","year":"2024","journal-title":"PLoS Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/pharmaceutics16050594","article-title":"Impact of LS mutation on pharmacokinetics of preventive HIV broadly neutralizing monoclonal antibodies: a cross-protocol analysis of 16 clinical trials in people without HIV","volume":"16","author":"Mayer","year":"2024","journal-title":"Pharm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(24)00247-9","article-title":"Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136\/HPTN 092): a first-in-human, open-l","volume":"12","author":"Edupuganti","year":"2025","journal-title":"Lancet HIV"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1016\/S2352-3018(25)00041-4","article-title":"Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults","volume":"12","author":"Wu","year":"2025","journal-title":"Lancet HIV"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1093\/infdis\/jiaf450","article-title":"VH3810109 Efficacy, safety, pharmacokinetics, and incidence of antidrug antibodies in adults with HIV-1 naive to antiretroviral therapy: bANNER study results","volume":"232","author":"Leone","year":"2025","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e181496","DOI":"10.1172\/jci.insight.181496","article-title":"Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection","volume":"10","author":"Happe","year":"2025","journal-title":"JCI Insight"},{"key":"B26","article-title":"VH3810109 (N6LS) efficacy and safety in adults who are virologically suppressed: the EMBRACE study","author":"Leone","year":"2025"},{"key":"B27","article-title":"Lenacapavir with bNAbs GS-5423 and GS-2872 dosed every 6 months in people with HIV","author":"Eron","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial","volume":"10","author":"Mahomed","year":"2023","journal-title":"Lancet HIV"},{"key":"B31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/infdis\/jiac041","article-title":"Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for human immunodeficiency virus prevention","volume":"226","author":"Mahomed","year":"2022","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"B33","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"B35","article-title":"RIO A randomised placebo-controlled study of 2 LS-bNAbs in people treated in early HIV","author":"Fidler","year":"2025"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJMe2101131","article-title":"The AMP trials\u2014a glass half full","volume":"384","author":"Walker","year":"2021","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11904-023-00686-6","article-title":"More than the infinite monkey theorem: nHP models in the development of a pediatric HIV cure","volume":"21","author":"Fonseca","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.1217550","article-title":"Natural SIV hosts: showing AIDS the door","volume":"335","author":"Chahroudi","year":"2012","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imr.12074","article-title":"Immunology of pediatric HIV infection","volume":"254","author":"Tobin","year":"2013","journal-title":"Immunol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12981-024-00691-8","article-title":"95-95-95 HIV indicators among children younger than 15 years in South Africa: results from the 2017 national HIV prevalence, incidence, behaviour, and communication survey","volume":"22","author":"Magobo","year":"2025","journal-title":"AIDS Res Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1216","DOI":"10.1002\/iid3.1216","article-title":"Preventing breast milk HIV transmission using broadly neutralizing monoclonal antibodies: one size does not fit all","volume":"12","author":"Van de Perre","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/diagnostics13152563","article-title":"Eliminating vertical transmission of HIV in South Africa: establishing a baseline for the global alliance to end AIDS in children","volume":"13","author":"Haeri Mazanderani","year":"2023","journal-title":"Diagn"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0307065","DOI":"10.1371\/journal.pone.0307065","article-title":"Correction: caregivers of children with HIV in Botswana prefer monthly IV broadly neutralizing antibodies (bNAbs) to daily oral ART","volume":"19","author":"Sakoi-Mosetlhi","year":"2024","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0318940","DOI":"10.1371\/journal.pone.0318940","article-title":"Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens","volume":"20","author":"Alba","year":"2025","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1093\/cid\/ciaf568","article-title":"Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the tatelo study","volume":"82","author":"Ajibola","year":"2026","journal-title":"Clin Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/v16060911","article-title":"The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention","volume":"16","author":"Thavarajah","year":"2024","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","first-page":"105948","DOI":"10.1016\/j.ebiom.2025.105948","article-title":"Phenotypic and epigenetic profiles of circulating NK cells in spontaneous HIV-1 controllers","volume":"120","author":"Huber","year":"2025","journal-title":"EBioMedicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12879-016-2092-z","article-title":"Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child","volume":"16","author":"Palma","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"piaf002","DOI":"10.1093\/jpids\/piaf002","article-title":"Safety, tolerability, and pharmacokinetics of long-acting broadly neutralizing HIV-1 monoclonal antibody VRC07\u2013523LS in newborn infants exposed to HIV-1","volume":"14","author":"Cunningham","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/infdis\/jiab229","article-title":"Safety, tolerability, and pharmacokinetics of a long-acting broadly neutralizing human immunodeficiency virus type 1 (HIV-1) monoclonal antibody VRC01LS in HIV-1\u2013exposed newborn infants","volume":"224","author":"McFarland","year":"2021","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/infdis\/jiz532","article-title":"Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants","volume":"222","author":"Cunningham","year":"2020","journal-title":"J Infect Dis"},{"key":"B52","article-title":"PedMAb1 trial: safety of two broadly neutralising antibodies, CAP256V2LS and VRC07-523LS, administered singly or concurrently at birth and 3 months to breastfeeding HIV-1 exposed neonates and infants born without HIV","author":"Scarlatti","year":"2025"},{"key":"B53","doi-asserted-by":"publisher","first-page":"eadh0004","DOI":"10.1126\/scitranslmed.adh0004","article-title":"Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana","volume":"15","author":"Shapiro","year":"2023","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/QAI.0000000000003033","article-title":"Safety and pharmacokinetics of intravenous 10-1074 and VRC01LS in young children","volume":"91","author":"Capparelli","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B55","article-title":"Phase I\/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance of HIV-1 infected cells in infants (IMPAACT 2008)","author":"Khaitan","year":"2022"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e25049","DOI":"10.1002\/jia2.25049","article-title":"Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries","volume":"21","author":"Penazzato","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6657112","DOI":"10.1155\/2021\/6657112","article-title":"Mortality and attrition rates within the first year of antiretroviral therapy initiation among people living with HIV in guangxi, China: an observational cohort study","volume":"2021","author":"Zhu","year":"2021","journal-title":"Biomed Res Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/QAI.0000000000003330","article-title":"Mortality among HIV-infected adults on antiretroviral therapy in southern Uganda","volume":"95","author":"Nabukalu","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B59","doi-asserted-by":"publisher","first-page":"104990","DOI":"10.1016\/j.idnow.2024.104990","article-title":"Changes in early HIV\/AIDS mortality rates in people initiating antiretroviral treatment between 2013 and 2023: a 10-year multicenter survival study in Senegal","volume":"54","author":"Wembulua","year":"2024","journal-title":"Infect Dis now"},{"key":"B60","doi-asserted-by":"publisher","first-page":"39291","DOI":"10.1038\/s41598-025-23129-1","article-title":"Risk factors for early mortality among HIV-positive adults on antiretroviral therapy in Ethiopian health facilities","volume":"15","author":"Yadecha","year":"2025","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","article-title":"Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies","volume":"11","author":"Trickey","year":"2024","journal-title":"Lancet HIV"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e2024067062","DOI":"10.1542\/peds.2024-067062","article-title":"The need for RSV prophylaxis in LMICs","volume":"154","author":"P\u00e9rez Casas","year":"2024","journal-title":"Peds"},{"key":"B63","year":"2024"},{"key":"B64","author":"Capparelli","year":"2026"},{"key":"B65","author":"McFarland","year":"2026"},{"key":"B66","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1186\/s12879-024-09588-3","article-title":"Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti\u2011HIV\u20111 monoclonal antibodies (bNAbs), given to HIV\u20111 exposed, uninfected neonates and infants: study protocol for a phase I trial","volume":"24","author":"Goga","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/QAI.0000000000003147","article-title":"Brief report: long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial","volume":"92","author":"Ajibola","year":"2023","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1833681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:39:02Z","timestamp":1784785142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1833681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":67,"alternative-id":["10.3389\/fped.2026.1833681"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1833681","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1833681"}}